JO
ODT

John Overdeck’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

John Overdeck’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-170,888
Closed -$231K – 4806
2021
Q4 		$231K Buy
170,888
+131,075
+329% +$310K ﹤0.01% 3825
2021
Q3 		$116K Sell
39,813
-350,771
-90% -$1.17M ﹤0.01% 4069
2021
Q2 		$1.36M Sell
390,584
-258,935
-40% -$889K ﹤0.01% 2208
2021
Q1 		$2.22M Buy
649,519
+298,491
+85% +$5.64M 0.01% 1620
2020
Q4 		$6.74M Buy
351,028
+37,257
+12% +$575K 0.02% 772
2020
Q3 		$4.21M Buy
+313,771
New +$8.89M 0.02% 882
2020
Q1 		– Sell
-19,322
Closed -$627K – 4048
2019
Q4 		$627K Sell
19,322
-40,159
-68% -$1.24M ﹤0.01% 2607
2019
Q3 		$1.55M Buy
+59,481
New +$1.99M 0.01% 1624

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

John Overdeck's ODT Position: Q1 2022 in Review

John Overdeck sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 170,888 shares — an estimated $231K sold.

John Overdeck first reported a position in ODT in Q3 2019 and held it in 8 quarters. The position peaked at $6.74M in Q4 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • John Overdeck reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • John Overdeck sold 170,888 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $231K.
  • John Overdeck first reported a position in Odonate Therapeutics, Inc. Common Stock in Q3 2019 and held it in 8 quarters.
  • John Overdeck's Odonate Therapeutics, Inc. Common Stock position peaked at $6.74M in Q4 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.